Radiopharmaceutical Solutions fromthoughttofinish

Radiopharmaceutical Solutions

The radiopharmaceutical industry is experiencing a renaissance, with unprecedented growth resulting from rapid advancements in targeting radiation through new therapies and increasing global investment. As radiopharmaceutical innovation accelerates, so do regulatory complexities.

ELIQUENT is a trusted partner to global radiopharmaceutical innovators. We understand the unique challenges and opportunities facing radiopharmaceutical innovators.

We understand the unique challenges and opportunities facing radiopharmaceutical innovators.  Our deep expertise, proven track record, and industry-first approach make us the ideal partner to guide radiopharmaceutical innovators through regulatory, quality, and safety requirements—ensuring efficient approvals and long-term compliance.

Unlike conventional pharmaceuticals, radiopharmaceuticals present unique regulatory, technical, and logistical challenges. Our expertise enables us to tackle the most critical challenges in radiopharmaceutical development and compliance with precision and efficiency.

ELIQUENT’s integrated regulatory, quality, and safety solutions are designed to support companies bringing their products to market and maintaining global compliance. Whether you’re developing a first-in-class radiopharmaceutical or managing the post-approval lifecycle of an existing product, ELIQUENT provides the expert guidance to ensure regulatory success.

Regulatory Strategy & Development

ELIQUENT supports innovators bringing products to market by  developing a strategic, well-planned approach that accounts for both drug and radiation regulations, nuclear medicine oversight, and clinical complexities. ELIQUENT guides clients through complexities with the following services:

Strategy Development: Tailored regulatory strategies for positron emission tomography (PET) imaging agents, theranostics (therapeutic and diagnostic combination products), and radiopharmaceuticals

Agency Interactions: Planning and preparation for regulatory agency interactions, including the FDA, EMA, and other global health authorities

Submission Support: Guidance on clinical trial design, regulatory submission pathways, and risk mitigation strategies

Regulatory Submissions & Market Authorization

ELIQUENT supports innovators bringing products to market by  developing a strategic, well-planned approach that accounts for both drug and radiation regulations, nuclear medicine oversight, and clinical complexities. Our regulatory submission and market authorization services include:

Clinical Trial Applications: Investigational New Drug (IND) application and Clinical Trial Application (CTA) preparation and submissions to initiate clinical studies

Dossier Development: Comprehensive dossier development, including Chemistry, Manufacturing, and Controls (CMC), nonclinical, and clinical components

Marketing Authorizations: Preparation and submissions for commercialization: Marketing Authorization Application (MAA), New Drug Application (NDA) & Biologics License Application (BLA)

Lifecycle Management & Regulatory Compliance

Once approved, ELIQUENT provides the ongoing lifecycle maintenance required by radiopharmaceutical products to ensure continued post-market compliance and enable long-term market expansion. ELIQUENT’s full-service approach bridges the product lifecycle to include:

Manufacturing & Distribution: Chemistry, Manufacturing, and Controls (CMC) updates including new manufacturing site additions, post-approval variations, and regulatory supplements to keep products compliant

Regulatory Requirements: Labeling and safety updates to meet evolving regulatory requirements

Market Expansion: Regulatory strategy for additional indications and global expansion into new markets such as the United States, European Union, and Asia-Pacific

ELIQUENT’s team of radiopharmaceutical experts – composed of professionals with firsthand experience in radiopharmaceutical regulatory pathways – collaborate seamlessly to unlock excellence across the product lifecycle.

Our proven track record of success in navigating complex regulatory landscapes makes us a trusted partner for radiopharmaceutical companies seeking strategic guidance, streamlined approvals, and long-term compliance solutions.

ELIQUENT appreciates the specialized regulatory approach required by radiopharmaceuticals – one that accounts for complex oversight, short-lived isotopes, evolving global requirements, and cutting-edge scientific advancements.

Our team of former regulators, industry leaders, and scientific experts has the hands-on experience and deep knowledge needed to help radiopharmaceutical companies navigate these unique challenges efficiently and successfully.

Managing Health and Nuclear Regulatory Requirements

The Challenge.

Unlike conventional pharmaceuticals, radiopharmaceuticals fall under both health and nuclear safety regulations, requiring companies to coordinate with multiple regulatory bodies.

Our Solution.

The ELIQUENT team has extensive experience harmonizing regulatory strategies that align both drug approval requirements and nuclear safety regulations.

Varying Regulatory Expectations Across Regions

The Challenge.

Regulatory requirements for radiopharmaceuticals vary widely between the United States, European Union, and Asia-Pacific, making global expansion difficult. A tailored approach is optimal.

Our Solution.

ELIQUENT provides tailored global regulatory strategies to meet country-specific requirements while maintaining efficiency.

Staying Ahead of Regulatory Trends for Novel Therapies

The Challenge.

The field of radiopharmaceuticals is evolving rapidly, particularly in theranostics and radiotherapeutics. Companies must proactively anticipate shifting regulatory expectations to avoid unnecessary delays in approvals.

Our Solution.

ELIQUENT works with companies to proactively anticipate shifting regulatory expectations to avoid unnecessary delays in approval.  Our experience enables the delivery of valuable insight throughout the product lifecycle.

Precision in Manufacturing and Clinical Trials

The Challenge.

Many radiopharmaceuticals have extremely short half-lives, requiring precise coordination between manufacturing, distribution, and administration to patients in clinical trials and commercial settings. The supply chain must be tightly controlled to avoid delays that could render the product unusable.

Our Solution.

ELIQUENT understands the time-sensitive nature of radiopharmaceuticals and offers regulatory strategies and expert guidance to optimize essential timelines.

Expertise beyond borders. ELIQUENT’S established and growing global presence spans the regulatory process and major markets. Our premier team of global regulatory experts support markets across the U.S., Europe, and Asia.

United States

ELIQUENT is a leading Food & Drug Administration (FDA) regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies.
Our experts have shaped the landscape of FDA regulatory policy and strategy for decades. We bring this unrivaled knowledge and unique insight to our work with clients every day.

Europe

The ELIQUENT team applies their deep and diverse knowledge of European regulations to keep clients in lock step with evolving global standards. With decades of experience in the European market, our team understands the intricacies of the European Medicines Agency (EMA) and offers tailored solutions to ensure products meet and exceed the needs of our clients.

Asia

ELIQUENT offers regionally specialized solutions for the innovators across Asia. Our comprehensive solutions include expert guidance to innovators seeking approval in Japan, the third-largest pharmaceutical market in the world. Explore ELIQUENT’s solutions for clients in Japan’s life sciences market.

Explore ELIQUENT Japan >>

Ready for regulatory clarity? Contact us.